Archives des IPO - Polypeptide

We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Filter by
Categories
Tags
Authors
Show all

All
Ad hoc announcements pursuant to Art. 53 LR
Media releases
Business news
Expert views

All
Polypeptide
Olivier Ludemann-Hombourger
Technology & Innovation
Mechanochemistry
Preparative & Process Scale HPLC
MCC and SFC
German CPhl worldwide Europe
Polpeptide Laboratories Sweden
cola dioxide emissions
TIDES Europe
Postillion Convention Center
Monika Casanova
HR
Baar
Cara Therapeutics
Steve O’Connor
Sophie Marechal
Dr. Raymond De Vré
Raymond De Vré
De Vré
NVX-CoV2373
Corona
Neil James Thompson
Draupnir Holding B.V
Growth
Christina Del Vecchio
Trishul Shah
Benign alcohols
green chemistry
resin
solvent
SPPS
SPPS waste
recycling
Marion Erny
The American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable
ACSGCI PR
J. Pawlas
T. Svensson and J. H. Rasmussen
RSC Adv
E. R. Lax and T. Shah
Royal Society of Chemistry
A. Swietlow and A. Lower
Benzylthiols
scavengers
Jan Pawlas
Thomas Svensson
Jon H. Rasmussen
26th APS Monterey
Robert Hagopian
Chimica Oggi
Chemistry Today
Oligonucleotides & Peptides
Speciality Chemicals Magazine
Olivier Ludemann-Homburger
Peptides
Dr R. Ravetti Duran
Dr O. Ludemann-Hombourger
revenue CAGR
EBITDA margin towards 30%
Life Science Business Award
Dr. Olivier Ludemann-Hombourger
Dr. Renan Revetti Duran
Jane Salik
Torrance community
Joint Global Coordinators
IPO
PolyPeptide Group AG
Swiss Stock Exchange
SIX
Christelle Bobier
Director Global Engineering and Manufacturing Technology
double-digit growth
Pipeline Projects
Ypso-Proxima® software
Solid Phase Peptide Synthesis
COVID-19
peptide-based therapies and vaccines
Braine-L’Alleud
PolyPeptide Group
Ph.D. Scientist
Global Development
Eran Benjamin
Global Director for Quality Control and Analytical Development
Medicon Valley Alliance
MVA
reducing solvent consumption
M. McCoy
Rodney Lax
M. Verlander
R. Lax
A. SWIETLOW
L. Anderson and J. Persson; PolyPeptide Group
Dec 2000
L. Andersson
L. Blomberg
M. Flegel
L. Lepsa
B. Nilsson
Biopolymers (Peptide Science)
Nov 2000
Marika Lundqvist
Mikael Nilsson and Jon H. Rasmussen
25th APS - P280
2017
Jul 2019
Mikael Nilsson
Biljana Antonic
Jens Finnman
TIDES Boston 2018 PM1
B. Antonic
M. Lundqvist
T. Svensson
J. Finnman
J. H. Rasmussen
2D Green SPPS: Green solvents for on-resin removal of acid sensitive protecting groups and lactamization
Green Chem.
2019
21
2594.
J. Pawlas and J. H. Rasmussen
5990. DOI: 10.1039/c9gc02775k
T. Nuijens
J. Persson
M. Schmidt
A. Toplak
M. Nilsson and J. H. Rasmussen
6451
DOI: 10.1039/c9gc03600h
Speciality Chemicals Magazine 37.01 January 2017
Speciality Chemicals Magazine May 2014
I. Eggen
B. Gregg
H. Rode
A. Szajek; BioPharm International
2014
May 2014
By Aleksander Swietlow
Harold Rode
Anita Szajek
Michael Verlander
Ivo Eggen
Brian Gregg; BioPharm International
Apr 2014
Speciality Chemicals Magazine May 2013
SciBX Collection: Macrocycles and Constrained Peptides
Apr 2013
BioPharm International
January 2013
1 Stefan Hansen
Thomas Svensson and Gunnar Stærkær
EuroPeptides 2012
Eugenia Pagans Lista
Dr. Vivek Khare
Roger Sundström
Dr. Jon Holbech Rasmussen; PharManufacturing: The International Peptide Review
Dec 2012
C. Meenan; Innovations in Pharmaceutical Technology / Issue 43
C. Meenan; Innovations in Pharmaceutical Technology / Issue 42
Sep 2012
Henrik Schou Sorensen; PharManufacturing: The International Peptide Review
Dec 2011
Jan Pawlas 1
Stefan Hansen 1
Anne H. Sørensen 1
Gunnar Stærkær 1
Anette Møller 1
Neil Thompson 1
Thomas Pagano 2
Fangming Kong 2
Steve Koza 2
Mark Pozzo 3
Jari Finneman 3
and Patricia Droege 3
31 st European Peptide Symposium 2010
Anders Tsirk
PhD; PharManufacturing: The International Peptide Review
Sep 2010
Chemistry Today - Pharma Horizon
Jan./Feb. 2019
Mar 2019

All
Patric Rombo
Peter Simonsson
PolyPeptide Group

Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide Group announces the exercise of the full over-allotment option

5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.